Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EXPRESS: CER-001 in Heterozygous Familial Hypercholesterolemia
NCT01515241Phase 2Completed
- Sponsor
- ABIONYX Pharma
- Start
- Jan 2012
- Primary completion
- Apr 2012
- Modality
- Recombinant Proteins and Enzymes, Nanoparticles
- Countries
- 1
01
Overview
A Phase 2 trial of CER-001 in heterozygous familial hypercholesterolemia (HeFH), sponsored by ABIONYX Pharma. Started Jan 2012; status: completed.
02
Drugs
CER-001
03
Conditions
heterozygous familial hypercholesterolemia (HeFH)
Beyond the preview
Go deeper on NCT01515241.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01515241.